Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04472663 · ClinicalTrials.gov registry record
Participant Reported Outcomes and Treatment Experiences in Kidney Cancer
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 5
- Enrollment target
NCT04472663 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 5 participants.
The verdict
NCT04472663 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
The purpose of this observational study is to collect contemporary real-world treatment patterns, clinical outcomes, humanistic burden (including patient-reported disease-specific Health-related Quality of Life (HRQoL), and treatment- related adverse events (AEs) or adverse reactions (ARs) among Advanced Renal Cell Carcinoma (aRCC) patients initiating first-line systemic therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2020-12-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04472663
The ClinicalTrials.gov registry entry for NCT04472663 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04472663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04472663 about?
NCT04472663 is a clinical study titled "Participant Reported Outcomes and Treatment Experiences in Kidney Cancer". The purpose of this observational study is to collect contemporary real-world treatment patterns, clinical outcomes, humanistic burden (including patient-reported disease-specific Health-related Quality of Life (HRQoL), and treatment- related adverse events (AEs) or adverse reactions (ARs) among Adv...
What is the current status of trial NCT04472663?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2020-07-06. Estimated completion is 2020-12-09.
Who is sponsoring clinical trial NCT04472663?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.